NCT05283044 Implementing Precision Medicine in cOmmunity HospiTALs
| NCT ID | NCT05283044 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris |
| Condition | Metastatic Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2022-06-29 |
| Primary Completion | 2028-11-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10,000 participants in total. It began in 2022-06-29 with a primary completion date of 2028-11-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective biomarker study that aims at demonstrating the impact of liquid biopsy to deliver better treatment for cancer patients with metastatic disease managed in the community setting
Eligibility Criteria
Inclusion Criteria: Participants are eligible to be included in the study only if they meet all of the following criteria: 1. Age ≥ 18 years 2. Histology: solid malignant tumor 3. Locally advanced/unresectable and/or metastatic (for prostate cancer: castration resistant prostate cancer, for RH+/HER2- breast cancer: prior treatment with endocrine therapy plus anti-CDK4/6 inhibitor) 4. Eastern Cooperative Oncology Group (ECOG) performance status \< 2 5. Measurable disease as per RECIST criteria 6. Patient with a social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code) 7. Voluntary signed and dated written informed consent prior to any study specific procedure. Exclusion Criteria: Participants will be excluded from the study if they meet any of the following criteria: 1. Radiological evidence of symptomatic or progressive brain metastases 2. Previous or current malignancies of others histologies within the last 2 years, with the exception of in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin and prostate cancer 3. Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in a clinical trial or which would jeopardize compliance with the protocol 4. Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent 5. Minors (Age \< 18 years) 6. Pregnant or breast-feeding women 7. Previous enrollment in the present study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05283044 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Metastatic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05283044 currently recruiting?
Yes, NCT05283044 is actively recruiting participants. Contact the research team at Benjamin.verret@gustaveroussy.fr for enrollment information.
Where is the NCT05283044 trial being conducted?
This trial is being conducted at Bayonne, France, Bligny, France, Bordeaux, France, Corbeil-Essonnes, France and 11 additional locations.
Who is sponsoring the NCT05283044 clinical trial?
NCT05283044 is sponsored by Gustave Roussy, Cancer Campus, Grand Paris. The trial plans to enroll 10,000 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.